Introduction {#sec1}
============

Psoriasis is a chronic, immunologic, multi-factor inflammatory skin disorder found globally in 1--3% of the population \[[@cit0001]--[@cit0003]\]. There are two peaks of incidence in psoriasis: 20--30 years of age and 50--60 years of age. Miller *et al.* \[[@cit0004]\] confirm, based on a broad meta-analysis, that psoriasis is associated with cardiovascular diseases -- ischemic heart disease, peripheral vessels disease and atherosclerosis, diabetes, arterial hypertension, dyslipidemia, and obesity \[[@cit0004]--[@cit0013]\]. Psoriatic patients show a higher risk of metabolic syndrome development, increasing with the disease severity \[[@cit0014]--[@cit0016]\]. Severe psoriasis is associated with an increased cardiovascular mortality rate, the risk of cerebral stroke and heart attack is increasing \[[@cit0017]\].

Transforming growth factor β (TGF-β) is a pleiotropic cytokine, with a dimeric polypeptide structure, built of 112 amino acids \[[@cit0018], [@cit0019]\]. TGF-β1 isoform is a cytokine circulating in the whole human body which affects a series of physiological and pathophysiological processes \[[@cit0020], [@cit0021]\]. TGF-β1 is mainly located in stratum corneum and stratum granulosum of the skin, TGF-β2 is also in stratum spinosum and TGF-β3 can be found in the basal layer and underneath \[[@cit0022]\]. TGF-β1 may also play an important role in psoriasis pathogenesis, where the signalling involving cytokines is disturbed \[[@cit0018]\].

Cyclosporin A (CsA) is a strong immunomodulatory and immunosuppressive medicine, which -- through the inhibition of calcineurin phosphatase -- prevents the transcription process of genes responsible for the synthesis of inflammatory cytokines necessary to activate T lymphocytes. The recommended average dose of CsA is 2.5--5 mg/kg body mass/day \[[@cit0023], [@cit0024]\]. Nevertheless, an initial dose should be 4--5 mg/kg of body mass, taken twice a day for 2--4 weeks, and then the dose is recommended to be gradually reduced \[[@cit0025]\].

Aim {#sec2}
===

The aim of this paper was to show which of TGF-β isoforms and its receptors change their transcription activity in the peripheral blood in psoriatic patients during an 84-day long observation of the effects of CsA therapy. Moreover, an attempt was made to determine the usefulness of testing mRNA expression of *TGF-*β*1--3* and its receptors *TGF-*β*RI--III* as supplementary molecular markers of lost sensitivity to the medicine.

Material and methods {#sec3}
====================

Whole blood {#sec3.1}
-----------

The study group consisted of 32 patients with psoriasis (20 men and 12 women) who gave their informed consent to participate in the trial, aged 30 to 60, treated with CsA due to psoriasis. The patients were taking CsA orally, at an average dose of 2.5--mg/kg of body mass in the morning and in the evening. Their whole blood was taken three times: on the day of therapy commencement (day 0, on day 42 and day 84 of therapy).

Total RNA extraction {#sec3.2}
--------------------

Total RNA was isolated from the whole blood with the use of FENOZOL (A&A Biotechnology, Gdańsk, Poland) in two stages. The first stage commenced with an addition of 800 μl of Fenozol to 500 μl of the whole blood. It was then vortexed and incubated for 10 min at 50°C. Upon another vortexing, 600 μl of chloroform was added and then it was vortexed and centrifuged at 4°C for 20 min at 13,000 rotations/min. The upper fraction containing RNA was transferred to a new test tube and 600 μl of isopropanol was added. The next stage involved freezing at a temperature of --20°C for the whole night, and it finished the first stage of RNA isolation. The second stage involved addition of 200 μl of D solution from β-mercaptoethanol, and 200 μl of isopropanol. The whole mixture was then frozen for 90 min at a temperature of --20°C. During the next stage, the samples were centrifuged at 4°C for 20 min at 13,000 rotations/min. Upon completion of centrifuging, the supernatant was decanted and then drained with the use of a paper towel. RNA residue was rinsed in 1000 μl of 70% ethanol and centrifuged for 10 min at 4°C at 10,000 rotations/min. The procedure was completed with drying off RNA extracts at ambient temperature. The extracts were evaluated in terms of their quality with the application of qualitative electrophoresis and in terms of their quantity by means of spectrophotometry with the use of GeneQuant II (Pharmacia Biotech).

Quantitative real-time reverse transcription polymerase chain reaction assay (RTqPCR) {#sec3.3}
-------------------------------------------------------------------------------------

The RT-qPCR reaction was conducted with the use of Opticon™ DNA Engine Sequence Detector (MJ Research Inc., Watertown, MA, USA) with the use of SYBR Green Quantitect RT-PCR Kit (Qiagen, Valencia, CA, USA). Thermal conditions for the conducted reaction were as follows: reverse transcription (RT) reaction was conducted at a temperature of 50°C for 30 min, amplification was conducted at the following temperatures: 95°C for 15 min; 42 two-stage cycles: 94°C for 30 s and 60°C for 60 s and final extension: 72°C for 30 s. Sequences of starters used in the reaction are given in [Table 1](#t0001){ref-type="table"}. The analysis was performed with the use of β-actin (ACTB) and GAPDH as endogenic controls.

###### 

Starter sequences used in the RTqPCR reaction

  --------------------------------------------------------------
  Gene            Oligonucleotide sequence
  --------------- ----------------------------------------------
  *TGF-*β*1*      Forward: 5'TGAACCGGCCTTTCCTGCTTCTCATG3'\
                  Reverse: 5'GCGGAAGTCAATGTACAGCTGCCGC3'

  *TGF-*β*2*      Forward: 5'TACTACGCCAAGGAGGTTTACAAA3'\
                  Reverse: 5'TTGTTCAGGCACTCTGGCTTT3'

  *TGF-*β*3*      Forward: 5'CTGGATTGTGGTTCCATGCA3'\
                  Reverse: 5'TCCCCGAATGCCTCACAT3'

  *TGF-*β*RI*     Forward: 5'-ACTGGCAGCTGTCATTGCTGGACCAG-3'\
                  Reverse: 5'-CTGAGCCAGAACCTGACGTTGTCATATCA-3'

  *TGF-*β*RII*    Forward: 5'-GGCTCAACCACCAGGGCATCCAGAT-3'\
                  Reverse: 5'-CTCCCCGAGAGCCTGTCCAGATGCT-3'

  *TGF-*β*RIII*   Forward: 5'-ACCGTGATGGGCATTGCGTTTGCA-3'\
                  Reverse: 5'-GTGCTCTGCGTGCTGCCGATGCTGT-3'

  *ACTB*          Forward: 5'-TCACCCACACTGTGCCCATCTACGA-3'\
                  Reverse: 5'-caGcGGaaccGctcattGccaatGG-3'

  *GAPDH*         Forward: 5'-GAAGGTGAAGGTCGGAGTC-3'\
                  Reverse: 5'-GAAGATGGTGATGGGATTC-3'
  --------------------------------------------------------------

Transcription activity was presented as the number of mRNA copies of a specific gene, converted into 1 μg of total RNA.

Ethics {#sec3.4}
------

Consent of the Bioethics Commission of Medical University of Silesia in Katowice/Poland no. KNW/0022/KB1/59/I/13/14.

Statistical analysis {#sec3.5}
--------------------

The statistical analysis of the results of the expression change in examined genes was performed with the use of a licensed version of Statistica 12 PL (StatSoft, Tulsa, Oklahoma, USA), assuming the statistical gravity factor of *p* \< 0.05. The analysis was performed with the use of non-parametric methods; the median, and upper and lower quartiles were used to describe the number of mRNA copies of gene/1 μg total RNA ([Table 2](#t0002){ref-type="table"}). The Kruskal-Wallis test was conducted, and in case of statistically significant differences between expressions of the individual TGF-β isoform and its *TGF-*β*Rs* receptors at a given moment -- a post-hoc multi-comparison test. The ANOVA Friedman test and post-hoc ANOVA Friedman were also performed in order to show the statistical significance of a given TGF-β isoform and its receptors on day 0, 42, and 84 of observation of the efficacy of CsA therapy.

###### 

Change in *TGF*β*1--3* and *TGF*β*I--III* transcription activity during 84 days of treatment

  Name of the group     mRNA            Median (the number of mRNA copies of gene/1 μg total RNA)   Lower quartile (the number of mRNA copies of gene/1 μg total RNA)   Upper quartile (the number of mRNA copies of gene/ 1 μg total RNA)   ANOVA Friedman test *p* \< 0.05
  --------------------- --------------- ----------------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------- ---------------------------------
  Day 0 of treatment    *TGF-*β*1*      497000                                                      190000                                                              873000                                                               \< 0.001
  Day 42 of treatment   394000          74500                                                       3060000                                                                                                                                  
  Day 84 of treatment   466500          152000                                                      2640000                                                                                                                                  
  Day 0 of treatment    *TGF-*β*2*      6790                                                        1160                                                                46800                                                                0.55
  Day 42 of treatment   2360            915                                                         72200                                                                                                                                    
  Day 84 of treatment   3615            672                                                         6520                                                                                                                                     
  Day 0 of treatment    *TGF-*β*3*      227500                                                      85650                                                               738500                                                               \< 0.001
  Day 42 of treatment   1030000         260000                                                      1770000                                                                                                                                  
  Day 84 of treatment   367000          52000                                                       879000                                                                                                                                   
  Day 0 of treatment    *TGF-*β*R*I     73400                                                       37200                                                               444000                                                               \< 0.001
  Day 42 of treatment   144500          94400                                                       794000                                                                                                                                   
  Day 84 of treatment   82050           15700                                                       904500                                                                                                                                   
  Day 0 of treatment    *TGF-*β*RII*    425000                                                      75300                                                               1010000                                                              0.00001
  Day 42 of treatment   360500          50700                                                       996000                                                                                                                                   
  Day 84 of treatment   247500          77400                                                       944500                                                                                                                                   
  Day 0 of treatment    *TGF-*β*RIII*   286500                                                      111000                                                              749000                                                               \< 0.001
  Day 42 of treatment   194000          100000                                                      930000                                                                                                                                   
  Day 84 of treatment   198000          123000                                                      474000                                                                                                                                   

Results {#sec4}
=======

With regard to *TGF-*β*1*, when compared with the observation commencement, we observed that on day 42 there was a decrease in the expression and on day 84 of exposure to the medicine, there occurred another increase in the number of transcripts of this gene. A similar trend is observed in case of *TGF-*β*2*. *TGF-*β*3* transcription activity increases after 42 days of treatment, however further prolongation of medicine administration decreases the expression with a likely tendency for the expression to reach the baseline level.

When analysing the expression of *TGF-*β*RI--III* receptors, it may be observed that the expressions of *TGF-*β*RII* and *TGF-*β*RIII* are continuously lower. Whereas, as far as *TGF-*β*RI* is concerned, we observe overexpression on day 42, when compared with the control sample (day 0), and twice longer period of CsA administration leads to a decreased transcription activity, the expression of which seems to be comparable to that of the control sample.

In order to determine statistically important differences of expressions of various TGF-βs isoform and its *TGF-*β*Rs* receptors, the Kruskal-Wallis test was conducted and, in case of statistically important differences -- a post-hoc multi-comparison test, too. Important differences of transcript quantities were determined between *TGF-*β*1* and *TGF-*β*2* (*p* \< 0.001) and between *TGF-*β*2* and *TGF-*β*3* (*p* \< 0.001) on each stage of the pharmacotherapy period (day 0, day 42, day 84). In case of receptors, there are no statistically significant differences of expressions at a given moment of therapy ([Figure 1](#f0001){ref-type="fig"}).

![TGF-β1--3 expression profile on the day of therapy commencement day 0 (**A**), on day 42 (**B**), on day 84 (**C**)](PDIA-35-77242-g001){#f0001}

When analysing variances in the expression profiles of the specific isoforms between the individual days of therapy, the ANOVA Friedman test was performed and, in case of statistically important differences -- post-hoc ANOVA Friedman, too.

In case of *TGF-*β*1* (*p* \< 0.001), statistically significant differences of expressions were determined between the following periods: day 0 and day 42, day 0 and day 84, and day 42 and day 84. In case of *TGF-*β*2*, the statistical analysis did not show any statistically significant differences in the expressions of this gene (*p* = 0.055). Statistically significant differences were determined in case of *TGF-*β3 (*p* \< 0.001) between the following: day 0 and day 42, and day 42 and day 84. ANOVA Friedman analysis showed that variances in the *TGF-*β*RI* and *TGF-*β*RII* expressions are statistically significant (*p* \< 0.001) and occur between day 0 and day 42, and day 42 and day 84. Also in case of *TGF-*β*RIII*, the ANOVA Friedman variance analysis showed that differences in the expression of this gene are statistically significant (*p* \< 0.001) and they may be observed between the following periods: day 0 to day 42 and day 0 to day 84 ([Figure 2](#f0002){ref-type="fig"}).

![TGF-βRI-III expression profile on the day of therapy commencement day 0 (**A**), on day 42 (**B**), on day 84 (**C**)](PDIA-35-77242-g002){#f0002}

Discussion {#sec5}
==========

Psoriasis is a chronic, inflammatory skin disorder with the prevalence from 0.9% to 8.5% \[[@cit0026]\]. Complex pathophysiology of psoriasis includes cooperation between keratinocytes of epidermis, T lymphocytes and endothelial cells. With regard to ethiopathogenesis, it is classified as the inflammatory disease through a strong and inseparable relationship with the immunological system, which translates into an increased concentration of pro-inflammatory cytokines \[[@cit0027]--[@cit0036]\].

Recently recommended pharmacotherapy includes: CsA, acitretin (second-generation synthetic retinoid), and biological medicines are used more and more often \[[@cit0028], [@cit0037], [@cit0038]\].

Keratinocyte proliferation and their incorrect differentiation, as well as focal infiltrations consisting of neutrophils and lymphocytes within the epidermis and dermis lead to release of a series of cytokines, which play a crucial role in the pathogenesis of psoriasis. That is why, current methods of psoriasis treatment are aimed to suppress inflammatory response through immunomodulation, affecting T lymphocytes, dendritic cells and keratinocytes. Cyclosporin A belongs to such medicines. It has also been applied to treat autoimmunologic diseases, such as atopic dermatitis and rheumatoid arthritis \[[@cit0039]--[@cit0041]\].

Cyclosporin A is used as one of the first-line drugs in the treatment of moderate and severe forms of psoriasis, defined through presence of the specific indexes: BSA \> 10, PASI \> 10 and DLQI \> 10 according to the European Consensus of Experts. It is a therapeutic drug with immunomodulatory properties through suppressing inflammatory cells. Cyclosporin A inhibits keratinocyte proliferation, as well as expression of ICAM-1 endothelial cell adhesion and E-selectin.

In their study, Abe *et al.* proved that CsA affects not only keratinocytes, but also skin fibroblasts, and the effects of its action depend on interleukin 6 (IL-6), the determinant of which is rebuilding of ECM and effect on immunocompetent cells \[[@cit0042]\]. Janikowska *et al.* also conducted trials concerning signalling paths where CsA plays a key role. The objective of the experiment was to evaluate the effect of CsA on the proliferation of healthy human skin fibroblasts through examination of variances in expression profiles of genes involved in the cellular cycle regulation and transcription processes \[[@cit0043]\].

Analogous trials with regard to CsA and its effect on psoriasis were conducted by Elango and Thirupathi, but with the use of methotrexate (MTX), which is also an immunosuppressive medicine. The aim of the trial was to find the pharmacological effect of MTX on the incorrect proliferation of keratinocytes and disturbed inflammatory response induced by uncontrollable expression of immunologic mediators. Results achieved by the said research team show a considerably reduced expression of mRNA gene encoding TNF-α and IFN-g and an increased expression of TGF-β 1 upon completion of MTX therapy (after 6 and 12 weeks) when compared with the period before exposure of psoriatic patients to methotrexate \[[@cit0044]\]. They show the efficacy and legitimacy of immunosuppressive therapy in psoriatic patients.

Transforming growth factor β is one of the most known pleiotropic and multi-purpose peptides, generated by various types of cells, taking part in many metabolic processes, including cellular proliferation, their differentiation, apoptosis and is generated in response to ongoing inflammation \[[@cit0045], [@cit0046]\]. Transforming growth factor β is a natural and strong growth inhibitor of various types of cells, including epithelial cells, endothelial cells and hematopoietic cells \[[@cit0047], [@cit0048]\]. Deregulation in the secretion and functions performed by TGF-β was documented in various skin diseases, including psoriasis, wound healing disorders, formation of hypertrophic scars and skin cancer. Moreover, this peptide is perceived as an efficient inhibitor of keratinocyte proliferation in psoriasis \[[@cit0045]\].

Transforming growth factor β1, which is a strong inhibitor of cellular proliferation, is synthesised as a precursor, separated inside cells in the form of inactive complex covering mature TGF-β1, non-covalently bound with a part of peptide (LAP) releasing directly from extracellular matrix \[[@cit0049], [@cit0050]\]. Extracellular activation of TGF-β1 occurs after its release from the complex. TGF-β then transmits the signal inside the cell through Smad2 and Smad3 phosphorylation. Following phosphorylation of protein and Smad2, they form a complex with Smad4, gather inside the nucleus and act as transcription agents. This cascade of events changes the gene expression in keratinocytes, which inhibits proliferation, increases diversification and susceptibility to apoptosis \[[@cit0051], [@cit0052]\].

On the basis of results of their research, Liu and Feng underline that CD109 protein may act synergistically with Smad7 protein, thus reducing TGF-βRI expression and lead to TGF-β signalling completion in psoriasis \[[@cit0045]\]. Zhang and Meng confirmed their hypothesis stating that TGF-β1 plays a role in the development of psoriatic pathological lesions by means of the mechanism triggered by Smad3 inhibitor. They conducted their experiment with the use of a transgenic K5 mouse model. Local treatment with the use of Smad3 inhibitor blocked TGF-β signalling, which in turn contributed to reduced advancement of psoriasis, reduced infiltration of intumescence from lymphocytes T CD3^+^ and macrophages and halting the fibrotic process in the skin. It involved considerably reduced quantities of TGF-β1 and IL-6, IL-23 and IL-17A. Managing TGF-β/Smad3 signalling with the use of Smad3 inhibitor may constitute a new and efficient option in psoriasis therapy \[[@cit0052]--[@cit0054]\].

In this paper, an attempt was made to assess changes in mRNA transcription activity of genes encoding isoforms of the β transforming growth factor: TGF-β1, TGF-β2, TGF-β3 and its receptors: TGF-βR1, TGF-βR2 and TGF-βR3 in patients with moderate and severe forms of psoriasis. They were examined on the basis of patients' whole blood, taken in accordance with the assumed standards. Material for transcriptome was taken thrice: before treatment (day 0), on day 42 and day 84 of the therapy.

Results of the research conducted at the transcriptome level aimed at deepening the knowledge on the disease ethiopathogenesis, basing on molecular mechanisms involving the development of inflammation present during the dermatosis and looking for supplementary diagnostic markers, as well as new therapeutic strategies.

In order to determine the therapeutic potential of CsA in the treatment of psoriasis and the possibility of using TGF-βs and its TGF-βR receptors as control markers of the said disease, interpretation of the profile variances in the genes encoding TGFβ1-3 and its TGFβRI-III receptors during the 84-day long therapy was also performed. When analysing the achieved results of expression profile variances of examined mRNA of genes, coupled with the clinical observation of patients, it is ascertained that the best molecular diagnostic marker is TGF-β1, when compared with the other TGFβ isoforms and their receptors, which are characterised by considerable heterogeneity of expression during the 84-day long observation of the efficacy of the CsA therapy. It could also be presumed so, taking into account the fact that an increased TGF-β1 expression correlated with the improved local condition of the skin in the course of psoriasis, which was observed during regular check-ups of the patients.

Conclusions {#sec6}
===========

Gene expression variances and signal transduction through a pleiotropic cytokine from the TGF-β family contributes to better ethiopathogenesis of psoriasis. However, further trials and analyses would be advisable at the level of transcriptome and proteome. Results of this study also indicate the efficacy of pharmacotherapy with the use of CsA and the legitimacy of molecular tests, which make it possible to analyse mechanisms underlying the inflammatory process, as well as underline the possibility of using TGF-β1 as a supplementary diagnostic marker in psoriasis. Determination of transcription activity variances of genes involving a given pathological process or cellular response to a given medicine is justified because molecular changes precede phenotypic changes. Consequently, introduction of determination of the mRNA level of the TGF-β1 isoform in the diagnostics and treatment would make it possible to detect psoriatic patients' sensitivity to CsA, enabling one to change the therapeutic strategy sufficiently early. The positive result would be the increased safety of the therapy and a decreased number of incidences and intensity of disease exacerbation due to the possible early loss of sensitivity to the drug, which does not reveal itself phenotypically.
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